| Document |
Document Title |
|
WO/2005/099702A2 |
The invention features derivatives of R(-)-11-hydroxyaporphines and methods of treating Parkinson'’ disease, sexual dysfunction, and depressive disorders therewith.
|
|
WO/2005/097713A1 |
A method for the fluoridation of an iodonium salt with a fluoride ion source which can be carried out in an aqueous reaction solvent.
|
|
WO/2005/097753A1 |
The invention relates to a method for preparing a compound of formula (I), wherein R and R2 = hydrogen or alkyl C1-C6, aryl C6-C10 or aralkyl C7-C12, consisting in reacting perylene tetracarboxylic dianhydride or naphtalic anhydride with...
|
|
WO/2005/097776A1 |
The invention relates to a cosmetic or pharmaceutical composition containing, in a physiologically-acceptable medium, at least one polymer comprising at least one novel monomeric compound having optical effect properties. The invention a...
|
|
WO/2005/097128A1 |
Disclosed are compounds having Formula (IV) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and p are as defined herein, for use in methods for treating, preventing or ameliorating hyperproliferative disorders, such...
|
|
WO/2005/092840A1 |
The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invent...
|
|
WO/2005/092895A2 |
This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 independently represent a hydrogen atom or the like; R3 repre...
|
|
WO/2005/092858A2 |
This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 independently represent a hydrogen atom or the like; R3 repre...
|
|
WO/2005/089094A2 |
The invention provides materials and methods for making anisotropic solids which may be in the form of films, layers, shaped elements, and other shaped articles. The methods provide anisotropic solids without the need for rolling, rubbin...
|
|
WO/2005/090310A2 |
A new process is described for synthesising cyclohexanediacetic acid monoamide, a key compound in the synthesis of grabapentin precursors. The process of the invention is characterised by reacting cyclohexanone with cynoacetamide and imm...
|
|
WO/2005/089294A2 |
Substituted indenoisoquinolinium compounds, and pharmaceutical formulations of substituted indenoisoquinolinium compounds are described. Also described are processes for preparing substituted indenoisoquinolinium compounds. Also describe...
|
|
WO/2005/090311A1 |
Compounds of formula (I) in which R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cydoalkoxy, 3-7C-cydoalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy, R2 is hydroxyl, 1-4C-aikoxy, 3-7C-cydoalkoxy, 3-7...
|
|
WO/2005/087744A1 |
Compounds of formula (I) in which R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy, R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy...
|
|
WO/2005/087745A1 |
Compounds of formula (I) in which R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or com pletely or predominantly fluorine-substituted 1-4C-alkoxy, R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkox...
|
|
WO/2005/085203A1 |
Compounds of a certain formula (I), in which R1, R2, R3, R31, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective PDE4 inhibitors.
|
|
WO/2005/084674A1 |
An amorphous form of desloratadine and processes for making the amorphous form as well as compositions, pharmaceutical compositions, and methods utilizing the crystalline form are provided.
|
|
WO2005037832B1 |
Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease...
|
|
WO/2005/084104A2 |
Compounds of a certain formula (I), in which R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly flurorine-substituted 1-4C-alkoxy, R2 is hydroxyl, 1-4C-alkoxy, 3-7C-c...
|
|
WO/2005/082856A2 |
The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I m...
|
|
WO/2005/082860A1 |
Tetracyclines are useful as calpain inhibitors, particularly inhibitors of calpain I and II, as demonstrated in enzymatic assays as well as at the cellular and animal levels. Tetracyclines may be used in the treatment of a wide range of ...
|
|
WO/2005/082368A1 |
The present invention relates to Isoquinoline Derivatives, compositions comprising an effective amount of a Isoquinoline Derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, an ischemic conditi...
|
|
WO/2005/082079A2 |
The present invention relates to Tetracyclic Lactam Derivatives, compositions comprising an effective amount of a Tetracyclic Lactam Derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, an isch...
|
|
WO/2005/080322A1 |
A novel fluorene characterized by having a fluorene skeleton to which a functional group such as a guanidino group is attached via a carbonyl group, or its salt. This compound has such an advantage as showing a high affinity particularly...
|
|
WO/2005/077906A1 |
Compounds of a certain formula (1), in which R1, R2, R3, R31, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective PDE4 inhibitors in which R7 is a radical of formulae (a), (b), (c) or (d).
|
|
WO/2005/076815A2 |
Mono- and diimide perylene and naphthalene compounds, N- and core substituted with electron-withdrawing groups, for use in the fabrication of various device structures.
|
|
WO/2005/075459A1 |
Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.
|
|
WO/2005/075574A1 |
The invention relates to the novel naphthalene dyestuffs of formula (I), and to dyes for keratin fibers, especially human hair, containing said compounds.
|
|
WO/2005/074872A1 |
The invention relates to the lightening cationic naphthalene dyestuffs of formula (I), and to dyes for keratin fibers, especially human hair, containing said compounds.
|
|
WO/2005/073204A1 |
The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and ot...
|
|
WO/2005/072732A1 |
A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-&kgreen B activity including obesity, diabetes, inflammatory and immun...
|
|
WO/2005/070895A1 |
The invention relates to a method for the production of terylene-3,4:11,12-tetracarboxydiimides (I) in which the variables have the following meanings: R, R' independently = H, optionally substituted alkyl or cycloalkyl, aryl or heteroar...
|
|
WO/2005/070894A1 |
The invention relates to a method for producing terrylen-3,4:11,12-tetracarboxylic acid diimids of general formula (I), wherein R and R' are independently hydrogen, possibly substituted C1-C30-alkyl, C5-C8-cycloalkyl, aryl or hetaryl con...
|
|
WO/2005/065779A1 |
The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment usin...
|
|
WO/2005/063680A1 |
The present invention provides a process for the preparation of arylamines comprises reacting aryl halide and aryl amine/heterocyclic amine. The said process is carried out in the presence of a solvent, catalyst and a base.
|
|
WO/2005/062894A2 |
Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D1 receptor agonist, and ad...
|
|
WO/2005/058890A2 |
The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacolog...
|
|
WO/2005/058836A1 |
An insecticidal compound of formula I wherein X is O or NR11 where R11 is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; Y is a single bond, C=O, C=S or S(O)m where m is 0, 1 or ...
|
|
WO/2005/054249A1 |
The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in t...
|
|
WO/2005/051302A2 |
Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R8, R9 and R10, W, X, and Z are as defined in the specification. Such compounds are MEK inhibitors and useful in the t...
|
|
WO/2005/051906A2 |
Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X, Y and Z are as defined in the specification. Such compounds are MEK inhibitors and are useful in th...
|
|
WO/2005/051317A2 |
Imidazo ring systems substituted at the 1-position, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine bi...
|
|
WO/2005/051301A2 |
Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the tre...
|
|
WO/2005/051300A2 |
Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, R10, R20, R21, and R22 are as defined in the specification. Such compounds are MFK inhibitors and useful i...
|
|
WO/2005/047258A2 |
The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, methods for treating...
|
|
WO/2005/047265A1 |
A description is given of the use of naphthalene-1,8-dicarboxylic monoimides of the formula (I), in which R1 is hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl or heteroaryl and R2 is a radical containing at le...
|
|
WO/2005/046683A1 |
Compounds are disclosed that have a formula represented by the following: Formula (I) The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals in...
|
|
WO/2005/042500A1 |
This invention provides novel arylindenopyridines and arylindenopyrimidines of formula (I), (II) wherein R1, R2, R3, R4, and X are as defined above, and pharmaceutical compositions comprising same, useful for treating disorders ameliorat...
|
|
WO/2005/043124A2 |
One aspect of the invention relates to 1,8-diarylnaphthalene compounds. In certain embodiments, a compound of the invention is an N-oxide of a 1,8-diarylnaphthalene. In certain embodiments, the aryl group is an optionally substituted acr...
|
|
WO/2005/037257A2 |
The invention relates to medicinally used substances which specifically inhibit peptidases splitting ala-p-nitroanilide. The invention further relates to the use of at least one such substance or at least one pharmaceutical or cosmetic c...
|
|
WO/2005/030791A2 |
The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
|
